Search results
Results From The WOW.Com Content Network
Dual-energy X-ray absorptiometry (DXA, or DEXA [1]) is a means of measuring bone mineral density (BMD) with spectral imaging. Two X-ray beams, with different energy levels, are aimed at the patient's bones. When soft tissue absorption is subtracted, the bone mineral density (BMD) can be determined from the absorption of each beam by bone. Dual ...
A scanner used to measure bone density using dual energy X-ray absorptiometry. Bone density, or bone mineral density, is the amount of bone mineral in bone tissue.The concept is of mass of mineral per volume of bone (relating to density in the physics sense), although clinically it is measured by proxy according to optical density per square centimetre of bone surface upon imaging. [1]
DXA scanners can be used to diagnose osteopenia or osteoporosis as well as to measure bone density over time as people age or undergo medical treatment or lifestyle changes. [23] Information from the DXA scanner creates a bone mineral density T-score by comparing a patient's density to the bone density of a healthy young person.
bone density studies for osteoporosis assessment Dual X-ray absorptiometry and laser technique (DXL) in the area of bone density studies for osteoporosis assessment is an improvement to the DXA Technique , adding an exact laser measurement of the thickness of the region scanned.
Under previous guidelines, 14.3 million people in the U.S. would be eligible for screening. The new recommendation will include an additional 5 million people, Dahut said. The prognosis for people ...
A wide variety of body composition measurement methods exist. The gold standard measurement technique for the 4-compartment model consists of a weight measurement, body density measurement using hydrostatic weighing or air displacement plethysmography, total body water calculation using isotope dilution analysis, and mineral content measurement by dual-energy X-ray absorptiometry (DEXA). [1]
The International Osteoporosis Foundation and the European Calcified Tissue Society recommend pharmacological therapy for osteoporosis in postmenopausal women and men ≥70 years, with a previous fragility fracture, or a dose equivalent of prednisone ≥7.5 mg daily for ≥3 months. For premenopausal women and men <50 years taking steroids for ...
About 22 million women and 5.5 million men in the European Union had osteoporosis in 2010. [15] In the United States in 2010, about 8 million women and between 1 and 2 million men had osteoporosis. [13] [16] White and Asian people are at greater risk. [3] The word "osteoporosis" is from the Greek terms for "porous bones". [17]